Ceftaroline fosamil salvage therapy: An option for reduced-vancomycin-susceptible MRSA bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 797-801

  Espedido, Björn A ^a,c   Jensen, Slade O ^a,c   Van Hal, Sebastiaan J ^b,d  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

'See saw' effect; Broth microdilution; MICE strips

Indexed keywords

CEFTAROLINE FOSAMIL; DAPTOMYCIN; PENICILLIN BINDING PROTEIN 2A; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CONTROLLED STUDY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; SALVAGE THERAPY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; ADULT; BACTEREMIA; CASE REPORT; DRUG EFFECTS; DRUG TOLERANCE; FEMALE; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; STAPHYLOCOCCAL INFECTIONS;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG TOLERANCE; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SALVAGE THERAPY; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84928177340     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku455     Document Type: Article

References (23)

1. van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012; 25: 362-86.
2. Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with b-lactam resistance in Staphylococcus aureus. J Bacteriol 1984; 158: 513-6.
3. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
4. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
5. van Hal SJ, Steen JA, Espedido BA et al. In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale? J Antimicrob Chemother 2014; 69: 363-7.
6. Howden BP, Davies JK, Johnson PDR et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
7. Ishikawa T, Matsunaga N, Tawada H et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37.
8. Kim S-H, Kim K-H, Kim H-B et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52: 192-7.
9. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptiblity Tests for Bacteria That Grow Aerobically: Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
10. van Hal SJ, Barbagiannakos T, Jones M et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66: 2284-97.
11. van Hal SJ, Jones M, Gosbell IB et al. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS ONE 2011; 6: e21217.
12. Saravolatz SN, Martin H, Pawlak J et al. Ceftaroline-heteroresistant Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 3133-6.
13. Turnidge J, Coombs G, Pearson J. 2011 Australian Group on Antimicrobial Resistance/AstraZeneca Ceftaroline Susceptibility Study Report. 2012; PROP1107.
14. Barber KE, Ireland CE, Bukavyn N et al. Observation of 'seesaw effect' with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther 2014; 3: 35-43.
15. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
16. Alm RA, McLaughlin RE, Kos VN et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 2014; 69: 2065-75.
17. MacGowan AP, Noel AR, Tomaselli S et al. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013; 57: 2451-6.
18. Zhanel GG, Rossnagel E, Nichol K et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillinresistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J Antimicrob Chemother 2011; 66:1301-5.
19. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycinintermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
20. Bhalodi AA, Hagihara M, Nicolau DP et al. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 2014; 58: 672-7.
21. Casapao AM, Davis SL, Barr VO et al. A large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 2014; 58: 2541-6.
22. Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: Case series and review of the literature. Int J Antimicrob Agents 2013; 42: 450-5.
23. Lin JC, Aung G, Johns S et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013; 19: 42-9.